Answers are grounded in this paper and cite their sources.
Introduction: An increased disposition to thrombosis demonstrated by laboratory methods in patients with solid malignancies develops due to the activating effect of tumour cells on the haemostatic system. The development of this activating effect results from interactions between tumour cells and various components of the coagulation system (coagulation factors, platelets, endothelial cells, and fibrinolytic system) which leads from a prothrombotic state to the clinically overt disorders of the haemostatic system. Objectives: In a retrospective analysis, the authors sought for an answer to the following question: What is the type and frequency of haemostatic disorders that occurred in a large population of patients with solid malignancies? Methods: Between 1996 and 2004, solid malignancies have been diagnosed in 1381 patients by histological and/or cytological examinations. Most of the patients had primary bronchopulmonary carcinoma ( n = 1140). In the other patients the malignancies were of mammary, colorectal, renal, vesical, thyroidal, and pancreatic localisation; mesothelioma was diagnosed in six patients. Based on the staging examinations, the majority of patients were in an advanced clinical stage. Type and frequency of haemostatic disorders occurring in patients with solid malignancies were studied, with special regard to the occurrence of venous thromboembolism. Particular attention was given to the role of non-malignant co-morbidity in the development of haemostatic disorders. Results: Clinically overt haemostatic disorders were observed in 397 (28.7%) of the 1381 patients with malignancies. Deep vein thrombosis and acute pulmonary embolism were the most frequent ones ( n = 305; 22%). Migrating superficial thrombophlebitis, septic thrombosis, acute diffuse intravascular coagulation, and microangiopathic haemolytic anaemia occurred in 71 patients (6.7%). In 40% of patients with malignant diseases and associated haemostatic disorders, non-malignant co-morbidity has been observed with the dominance of various cardiac diseases as well as chronic obstructive pulmonary disease. In addition to the systemic causes leading to an increased disposition to thrombosis, the significantly increased local-regional tumour mass also contributed to the development of venous circulation disorder. Conclusions: Active cancer is often associated with a hypercoagulable state, which perturbs the haemostatic balance between anticoagulant and procoagulant forces, creating a prothrombotic state. The interaction between tumour cells and host cells involves a direct cell-to-cell interaction or an indirect mechanism by cytokine release. The hypercoagulable state in patients with a malignant disease may result in the occurrence of various clinically identifiable haemostatic system disorders: the most frequent one is venous thromboembolism (so-called secondary thrombosis). In cases of idiopathic venous thromboembolism, targeted examinations are warranted in order to prove or to preclude asymptomatic malignant diseases.
No takes yet. Share an insight, caveat, or question.
Bozóky et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: